Indeed, the mice with glioma that were treated with lymphatic protein blockers, such as chemokine (C-C motif) ligand 21 (CCL21) and C chemokine receptor type 7 (CCR7), did not demonstrate improvements after receiving this anti-tumor therapy. This evidence concerns the gene CCL21 and central nervous system cancer.